New Logo.png
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
June 23, 2022 09:41 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 23, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s shareholders have approved the proposals of Provectus’ Board of Directors (Board) to seek...
NOVARTIS logo.jpg
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
June 22, 2022 19:12 ET | Novartis Pharma AG
Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with...
Summit-logo-RGB.png
Summit Therapeutics Announces $100 Million Rights Offering
June 22, 2022 16:30 ET | Summit Therapeutics Inc.
Menlo Park, CA, June 22, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has approved a rights...
POINT-Logo-Colour (1).png
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial
June 21, 2022 08:30 ET | POINT Biopharma
Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer...
theralase_logo_destroying_cancer.png
Theralase® Phase Ib NMIBC Clinical Study Published
June 21, 2022 07:00 ET | Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
TIP_link_300x300.jpg
Precision Diagnostics Market Size, $168Bn by 2028, 13.3% CAGR Lead by Genetic Tests Segment, Global Forecast & Analysis by The Insight Partners
June 20, 2022 06:05 ET | The Insight Partners
New York, June 20, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Precision Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type...
ITM_Logo_Claim_RGB_high-res.png
ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress
June 15, 2022 05:00 ET | ITM Isotope Technologies Munich SE
Garching / Munich, June 15, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host an industry-sponsored lunch symposium on...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Announces Chief Financial Officer Transition Plan
June 14, 2022 16:30 ET | Sema4
Appoints Richard Miao, Sema4’s Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE...
Cancer Support Community Celebrates Inaugural Community Is Stronger Than Cancer Day
June 14, 2022 12:30 ET | Cancer Support Community
WASHINGTON, D.C., June 14, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) has designated June 28 as Community Is Stronger Than Cancer Day to celebrate the dedication and passion of its...
SYA dark blue font on white background (1).jpg
Syapse and Pierian Announce Genomics Collaboration to Power Precision Oncology
June 14, 2022 10:00 ET | Syapse
SAN FRANCISCO, June 14, 2022 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company announced with Pierian®, a global leader in advanced clinical genomics technology, a new joint...